Published in Psychopharmacology (Berl) on February 01, 2001
Are adolescents more vulnerable to drug addiction than adults? Evidence from animal models. Psychopharmacology (Berl) (2009) 2.06
Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry (2010) 1.75
The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend (2008) 1.68
Clinical laboratory assessment of the abuse liability of an electronic cigarette. Addiction (2012) 1.62
The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend (2008) 1.60
Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology (2010) 1.36
Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl) (2010) 1.31
Sensitization of the reinforcing effects of self-administered cocaine in rats: effects of dose and intravenous injection speed. Eur J Neurosci (2005) 1.29
Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology (2005) 1.28
Smoking produces rapid rise of [11C]nicotine in human brain. Psychopharmacology (Berl) (2010) 1.28
A pharmacological analysis of stimulant-induced increases in smoking. Psychopharmacology (Berl) (2007) 1.11
Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend (2009) 1.02
Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats. Psychopharmacology (Berl) (2005) 1.02
Effect of rate of delivery of intravenous cocaine on self-administration in rats. Pharmacol Biochem Behav (2009) 1.01
Brain temperature change and movement activation induced by intravenous cocaine delivered at various injection speeds in rats. Psychopharmacology (Berl) (2005) 1.01
Agonist replacement therapy for cocaine dependence: a translational review. Future Med Chem (2012) 0.97
The rate of intravenous cocaine or amphetamine delivery does not influence drug-taking and drug-seeking behavior in rats. Pharmacol Biochem Behav (2008) 0.92
Rats markedly escalate their intake and show a persistent susceptibility to reinstatement only when cocaine is injected rapidly. J Neurosci (2010) 0.92
A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. Addiction (2013) 0.90
Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology (Berl) (2014) 0.87
Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend (2012) 0.87
Animal models of cannabinoid reward. Br J Pharmacol (2010) 0.84
Neuroimaging and drug taking in primates. Psychopharmacology (Berl) (2011) 0.83
Low and high affinity dopamine transporter inhibitors block dopamine uptake within 5 sec of intravenous injection. Neuroscience (2011) 0.82
The future potential for cocaine vaccines. Expert Opin Biol Ther (2014) 0.82
Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology (2005) 0.82
Rapid delivery of cocaine facilitates acquisition of self-administration in rats: an effect masked by paired stimuli. Pharmacol Biochem Behav (2011) 0.82
Behavioral economic analysis of drug preference using multiple choice procedure data. Drug Alcohol Depend (2007) 0.81
Reevaluating the nicotine delivery kinetics hypothesis. Psychopharmacology (Berl) (2007) 0.81
Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist. J Pharmacol Exp Ther (2016) 0.81
Harmful microinjecting practices among a cohort of injection drug users in vancouver Canada. Subst Use Misuse (2010) 0.80
Cocaine withdrawal in rats selectively bred for low (LoS) versus high (HiS) saccharin intake. Pharmacol Biochem Behav (2014) 0.80
Intravenous saline injection as an interoceptive signal in rats. Psychopharmacology (Berl) (2011) 0.79
Carrier-mediated cocaine transport at the blood-brain barrier as a putative mechanism in addiction liability. Int J Neuropsychopharmacol (2014) 0.79
Impact of P-glycoprotein at the blood-brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties. Psychopharmacology (Berl) (2014) 0.78
Designing opioids that deter abuse. Pain Res Treat (2012) 0.78
Cues paired with either rapid or slower self-administered cocaine injections acquire similar conditioned rewarding properties. PLoS One (2011) 0.78
The speed of cocaine delivery determines the subsequent motivation to self-administer the drug. Neuropsychopharmacology (2013) 0.78
The self-administration of rapidly delivered cocaine promotes increased motivation to take the drug: contributions of prior levels of operant responding and cocaine intake. Psychopharmacology (Berl) (2014) 0.77
Prenatal IV Cocaine: Alterations in Auditory Information Processing. Front Psychiatry (2011) 0.77
Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users. Psychopharmacology (Berl) (2013) 0.77
The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue. Neuropharmacology (2015) 0.76
Individual differences in timing of peak positive subjective responses to d-amphetamine: Relationship to pharmacokinetics and physiology. J Psychopharmacol (2016) 0.76
The effects of oral d-amphetamine on impulsivity in smoked and intranasal cocaine users. Drug Alcohol Depend (2016) 0.75
Cognitive performance profiles by latent classes of drug use. Am J Addict (2014) 0.75
Once-daily medications for the pharmacological management of ADHD in adults. Ther Clin Risk Manag (2009) 0.75
Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers. Drug Alcohol Depend (2016) 0.75
Characterizing the relationship between increases in the cost of nicotine and decreases in nicotine content in adult male rats: implications for tobacco regulation. Psychopharmacology (Berl) (2016) 0.75
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med (2000) 6.65
Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA (1999) 5.29
A reinforcement-based therapeutic workplace for the treatment of drug abuse: six-month abstinence outcomes. Exp Clin Psychopharmacol (2001) 4.46
Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry (1997) 3.67
Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther (1994) 2.90
Providing medical care to methadone clinic patients: referral vs on-site care. Am J Public Health (1994) 2.79
A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther (1988) 2.32
The older smoker. Status, challenges and opportunities for intervention. Chest (1990) 2.32
Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharmacology (Berl) (1999) 2.30
Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther (2011) 1.74
Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther (1995) 1.73
Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry (1994) 1.70
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther (1988) 1.68
The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend (2008) 1.68
Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) (2001) 1.68
Does tailoring matter? The impact of a tailored guide on ratings and short-term smoking-related outcomes for older smokers. Health Educ Res (1994) 1.65
Voucher-based reinforcement of opiate plus cocaine abstinence in treatment-resistant methadone patients: effects of reinforcer magnitude. Exp Clin Psychopharmacol (2001) 1.62
Contingent reinforcement for carbon monoxide reduction: within-subject effects of pay amount. J Appl Behav Anal (1984) 1.58
A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend (1995) 1.54
The effects of a cooperation contingency on behavior in a continuous three-person environment. J Exp Anal Behav (1976) 1.50
Contingent payment procedures for smoking reduction and cessation. J Appl Behav Anal (1986) 1.45
Is there a learning curve associated with the use of remifentanil? Anesth Analg (2000) 1.44
Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) (1995) 1.42
Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther (1996) 1.41
Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J Pharmacol Exp Ther (2001) 1.41
Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) (2001) 1.41
Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med (1993) 1.41
A self-help intervention for African American smokers: tailoring cancer information service counseling for a special population. Prev Med (1998) 1.39
Validity of intravenous drug abusers' self-reported changes in HIV high-risk drug use behaviors. Drug Alcohol Depend (1995) 1.36
Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl) (2000) 1.36
Reducing drug use among methadone maintenance clients: contingent reinforcement for morphine-free urines. Addict Behav (1980) 1.35
Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol (1996) 1.35
Facilitation of human tobacco self-administration by ethanol: a behavioral analysis. J Exp Anal Behav (1976) 1.26
Voucher-based reinforcement of attendance by unemployed methadone patients in a job skills training program. Drug Alcohol Depend (1996) 1.24
Contingent methadone delivery: effects on illicit-opiate use. Drug Alcohol Depend (1986) 1.23
Effect of methadone dose contingencies on urinalysis test results of polydrug-abusing methadone-maintenance patients. Drug Alcohol Depend (1986) 1.23
Contingent reinforcement for benzodiazepine-free urines: evaluation of a drug abuse treatment intervention. J Appl Behav Anal (1982) 1.22
The role of behavioral contingency management in drug abuse treatment. NIDA Res Monogr (1984) 1.22
Contingent reinforcement for reduced carbon monoxide levels in cigarette smokers. Addict Behav (1982) 1.20
Human cigarette smoking: manipulation of number of puffs per bout, interbout interval and nicotine dose. J Pharmacol Exp Ther (1982) 1.20
Drug discrimination in human postaddicts: agonist-antagonist opioids. J Pharmacol Exp Ther (1989) 1.19
Reducing benzodiazepine self-administration with contingent reinforcement. Addict Behav (1979) 1.18
Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther (1995) 1.15
The effects of contingent payment and frequent workplace monitoring on smoking abstinence. Addict Behav (1989) 1.15
Quit Today! A targeted communications campaign to increase use of the cancer information service by African American smokers. Prev Med (1998) 1.14
Alcohol and secobarbital effects as a function of familial alcoholism: extended intoxication and increased withdrawal effects. Alcohol Clin Exp Res (1991) 1.13
Antisocial personality disorder and HIV infection among intravenous drug abusers. Am J Psychiatry (1993) 1.13
The brief abstinence test: voucher-based reinforcement of cocaine abstinence. Drug Alcohol Depend (2000) 1.12
Contingent reinforcement for reduced breath carbon monoxide levels: target-specific effects on cigarette smoking. Addict Behav (1985) 1.12
Contingency management in methadone maintenance: effects of reinforcing and aversive consequences on illicit polydrug use. Drug Alcohol Depend (1988) 1.11
Early treatment time course of depressive symptoms in opiate addicts. J Nerv Ment Dis (1991) 1.11
Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl) (1999) 1.10
Gradual dose taper following chronic buprenorphine. Am J Addict (2001) 1.10
Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. J Anal Toxicol (2000) 1.07
Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl) (1994) 1.07
A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for quantitation of cocaine and benzoylecgonine in human plasma. J Anal Toxicol (2001) 1.06
Contingency management approaches to drug self-administration and drug abuse: efficacy and limitations. Addict Behav (1981) 1.05
Genetic basis for expression of the major globotetraose-containing lipopolysaccharide from H. influenzae strain Rd (RM118). Glycobiology (2001) 1.04
Intravenous drug abusers with antisocial personality disorder: increased HIV risk behavior. Drug Alcohol Depend (1990) 1.04
The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology (Berl) (1997) 1.04
Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol (1994) 1.04
A national survey of older smokers: treatment needs of a growing population. Health Psychol (1991) 1.03
Incongruity between occupational interests and academic skills in drug abusing women. Drug Alcohol Depend (1995) 1.03
Literacy assessment of family health history tools for public health prevention. Public Health Genomics (2010) 1.03
Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline. J Pharmacol Exp Ther (1987) 1.02
Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology (Berl) (2001) 1.01
The relationships among knowledge, self-efficacy, preparedness, decisional conflict, and decisions to participate in a cancer clinical trial. Psychooncology (2012) 1.00
Alcohol expectancies and changes in beer consumption of first-year college students. Addict Behav (1995) 1.00
Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther (1992) 0.99
Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther (1996) 0.99
Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. J Pharmacol Exp Ther (2000) 0.99
Reinforcing effects of caffeine in coffee and capsules. J Exp Anal Behav (1989) 0.98
Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect. J Pharmacol Exp Ther (1989) 0.98
Validity of patients' self-reported drug use as a function of treatment status. Drug Alcohol Depend (1992) 0.97
Concurrent hereditary haemochromatosis and idiopathic Parkinson's disease: a case report series. J Neurol Neurosurg Psychiatry (2004) 0.97
Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo. J Pharmacol Exp Ther (1980) 0.96
Acute physical dependence in man: effects of naloxone after brief morphine exposure. J Pharmacol Exp Ther (1988) 0.96
Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl) (1988) 0.96
Human coffee drinking: reinforcing and physical dependence producing effects of caffeine. J Pharmacol Exp Ther (1986) 0.96
Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology (Berl) (1997) 0.96
Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose. Behav Pharmacol (1998) 0.96
HIV risk behavior in drug users: increased blood "booting" during cocaine injection. AIDS Educ Prev (1992) 0.95
Antisocial behavior of intravenous drug abusers: implications for diagnosis of antisocial personality disorder. Am J Psychiatry (1992) 0.95
Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. J Clin Pharmacol (2011) 0.95
Antagonist effects of nalbuphine in opioid-dependent human volunteers. J Pharmacol Exp Ther (1989) 0.95
Oral methadone self-administration: effects of dose and alternative reinforcers. Clin Pharmacol Ther (1983) 0.94
Modulation of intravenous cocaine effects by chronic oral cocaine in humans. Psychopharmacology (Berl) (2000) 0.94
A behavioral treatment of alcoholic methadone patients. Ann Intern Med (1978) 0.94
Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure. J Pharmacol Exp Ther (1989) 0.93
Methadone dose and treatment outcome. Drug Alcohol Depend (1993) 0.93
Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatry (1998) 0.93
Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther (1993) 0.91
Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans. Drug Alcohol Depend (2001) 0.90
Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend (1990) 0.90